Simon Ducharme obtains funding from The Association for Fronto-temporal Degeneration and the Alzheimer’s Drug Discovery Foundation

Dr. Simon Ducharme was awarded funding to support a project aiming to evaluate nabilone, a drug that targets the brain’s endocannabinoid system, as a symptomatic treatment in fronto-temporal degeneration. The endocannabinoid system is a chemical signalling pathway linked to neuroinflammation and other neurodegenerative processes, This work is based on previous data in Alzheimer's disease showing that nabilone can improve behavioural symptoms, and marks the first clinical trial for nabilone in fronto-temporal degeneration.

Congratulations Dr. Ducharme!

For more information.